424 related articles for article (PubMed ID: 26380086)
1. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.
Tarhini AA; Zahoor H; Lin Y; Malhotra U; Sander C; Butterfield LH; Kirkwood JM
J Immunother Cancer; 2015; 3():39. PubMed ID: 26380086
[TBL] [Abstract][Full Text] [Related]
2. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
Tarhini AA; Edington H; Butterfield LH; Lin Y; Shuai Y; Tawbi H; Sander C; Yin Y; Holtzman M; Johnson J; Rao UN; Kirkwood JM
PLoS One; 2014; 9(2):e87705. PubMed ID: 24498358
[TBL] [Abstract][Full Text] [Related]
3. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
4. Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.
Najjar YG; Ding F; Lin Y; VanderWeele R; Butterfield LH; Tarhini AA
J Transl Med; 2017 Feb; 15(1):39. PubMed ID: 28222797
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.
Retseck J; VanderWeele R; Lin HM; Lin Y; Butterfield LH; Tarhini AA
J Immunother Cancer; 2016; 4():38. PubMed ID: 27330811
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M
J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592
[TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.
Buchbinder EI; Gunturi A; Perritt J; Dutcher J; Aung S; Kaufman HL; Ernstoff MS; Miletello GP; Curti BD; Daniels GA; Patel SP; Kirkwood JM; Hallmeyer S; Clark JI; Gonzalez R; Richart JM; Lutzky J; Morse MA; Sullivan RJ; McDermott DF
J Immunother Cancer; 2016; 4():52. PubMed ID: 27660706
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Weber J; Thompson JA; Hamid O; Minor D; Amin A; Ron I; Ridolfi R; Assi H; Maraveyas A; Berman D; Siegel J; O'Day SJ
Clin Cancer Res; 2009 Sep; 15(17):5591-8. PubMed ID: 19671877
[TBL] [Abstract][Full Text] [Related]
9. Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit.
Tarhini AA; Lin Y; Lin HM; Vallabhaneni P; Sander C; LaFramboise W; Hamieh L
Oncoimmunology; 2017; 6(2):e1231291. PubMed ID: 28344862
[No Abstract] [Full Text] [Related]
10. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
11. A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab.
Kobeissi I; Eljilany I; Achkar T; LaFramboise WA; Santana-Santos L; Tarhini AA
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175874
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
[TBL] [Abstract][Full Text] [Related]
13. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.
Joseph RW; Eckel-Passow JE; Sharma R; Liu P; Parker A; Jakob J; Buchbinder E; Bassett RL; Davies MA; Hwu P; Atkins MB; Sullivan RJ
J Immunother; 2012; 35(9):711-5. PubMed ID: 23090080
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
[TBL] [Abstract][Full Text] [Related]
16. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.
Hardy-Werbin M; Rocha P; Arpi O; Taus Á; Nonell L; Durán X; Villanueva X; Joseph-Pietras D; Nolan L; Danson S; Griffiths R; Lopez-Botet M; Rovira A; Albanell J; Ottensmeier C; Arriola E
Oncoimmunology; 2019; 8(6):e1593810. PubMed ID: 31069160
[No Abstract] [Full Text] [Related]
18. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
19. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
